Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/14322
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavies, B.en
dc.contributor.authorColler, J.en
dc.contributor.authorJames, H.en
dc.contributor.authorGillis, D.en
dc.contributor.authorSomogyi, A.en
dc.contributor.authorHorowitz, J.en
dc.contributor.authorMorris, R.en
dc.contributor.authorSallustio, B.en
dc.date.issued2004en
dc.identifier.citationBritish Journal of Clinical Pharmacology, 2004; 57(4):456-463en
dc.identifier.issn0306-5251en
dc.identifier.issn1365-2125en
dc.identifier.urihttp://hdl.handle.net/2440/14322-
dc.description.abstractAims - Perhexiline is an antianginal agent that displays both saturable and polymorphic metabolism via CYP2D6. The aim of this study was to determine whether perhexiline produces clinically significant inhibition of CYP2D6-catalysed metabolism in angina patients. Methods - The effects of perhexiline on CYP2D6-catalysed metabolism were investigated by comparing urinary total dextrorphan/dextromethorphan metabolic ratios following a single dose of dextromethorphan (16.4 mg) in eight matched control patients not taking perhexiline and 24 patients taking perhexiline. All of the patients taking perhexiline had blood drawn for CYP2D6 genotyping as well as to measure plasma perhexiline and cis -OH-perhexiline concentrations. Results - Median (range) dextrorphan/dextromethorphan metabolic ratios were significantly higher ( P < 0.0001) in control patients, 271.1 (40.3–686.1), compared with perhexiline- treated patients, 5.0 (0.3–107.9). In the perhexiline-treated group 10/24 patients had metabolic ratios consistent with poor metabolizer phenotypes; however, none was a genotypic poor metabolizer. Interestingly, 89% of patients who had phenocopied to poor metabolizers had only one functional CYP2D6 gene. There was a significant negative linear correlation between the log of the dextrorphan/dextromethorphan metabolic ratio and plasma perhexiline concentrations ( r 2 = 0.69, P < 0.0001). Compared with patients with at least two functional CYP2D6 genes, those with one functional gene were on similar perhexiline dosage regimens but had significantly higher plasma perhexiline concentrations, 0.73 (0.21–1.00) vs. 0.36 (0.04–0.69) mg l - 1 ( P = 0.04), lower cis -OH-perhexiline/perhexiline ratios, 2.85 (0.35–6.10) vs. 6.51 (1.84–11.67) ( P = 0.03), and lower dextrorphan/dextromethorphan metabolic ratios, 2.51 (0.33–39.56) vs. 11.80 (2.90–36.93) ( P = 0.005). Conclusions - Perhexiline significantly inhibits CYP2D6-catalysed metabolism in angina patients. The plasma cis -OH-perhexiline/perhexiline ratio may help to both phenotype patients and predict those in whom perhexiline may be most likely to cause clinically significant metabolic inhibition.en
dc.description.statementofresponsibilityBenjamin J. L. Davies, Janet K. Coller, Heather M. James, David Gillis, Andrew A. Somogyi, John D. Horowitz, Raymond G. Morris & Benedetta C. Sallustioen
dc.language.isoenen
dc.publisherBlackwell Publishing Ltden
dc.subjectHumans; Angina Pectoris; Dextrorphan; Dextromethorphan; Perhexiline; Cytochrome P-450 CYP2D6; Cardiovascular Agents; Aged; Female; Maleen
dc.titleClinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineen
dc.typeJournal articleen
dc.identifier.rmid0020032085en
dc.identifier.doi10.1046/j.1365-2125.2003.02033.xen
dc.identifier.pubid57729-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidColler, J. [0000-0002-8273-5048]en
dc.identifier.orcidSomogyi, A. [0000-0003-4779-0380]en
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]en
dc.identifier.orcidSallustio, B. [0000-0002-0186-3073]en
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.